Sign in

You're signed outSign in or to get full access.

Lewis Titterton Jr.

Lead Independent Director at Anixa Biosciences
Board

About Lewis H. Titterton, Jr.

Independent director and Lead Independent Director of Anixa Biosciences (ANIX). Age 80; on ANIX’s board since July 2017, with prior service July 1999–January 2003 and August 2010–August 2016; served as Chairman (2012–2016) and Interim CEO (Aug–Sep 2012). MBA, SUNY Albany; BA, Cornell. Background in high technology and healthcare; designated Audit Committee financial expert .

Past Roles

OrganizationRoleTenureCommittees/Impact
Anixa Biosciences (ANIX)Director; Lead Independent DirectorDirector since Jul 2017; Lead Independent Director since Jul 2018; also director Jul 1999–Jan 2003; Aug 2010–Aug 2016Lead independent responsibilities include presiding at independent director sessions and liaison with Chair/CEO
Anixa Biosciences (ANIX)Chairman of the BoardJul 2012–Aug 2016Board leadership
Anixa Biosciences (ANIX)Interim Chief Executive OfficerAug 2012–Sep 2012Executive leadership during transition
NYMED, Inc. (diversified health services)Chairman of the Board1989–Oct 2018Healthcare operating and board oversight experience
MedE America, Inc.FounderFounded 1986Health-tech entrepreneurship
Management and Planning Services, Inc.Chief Executive Officer1978–1986Executive management

External Roles

OrganizationRoleTenureNotes/Committees
ParkerVision, Inc. (public)DirectorSince Jun 2023; previously Sep 2018–Apr 2019Public company board service (wireless technology)

Board Governance

AttributeDetails
IndependenceIndependent director; Board majority independent (Baskies, Gottschalk, Titterton)
Board leadershipLead Independent Director since July 2018; role includes presiding at meetings without Chair/CEO and serving as liaison
CommitteesAudit (Chair); Compensation (Chair); Nominating & Corporate Governance (Member)
Audit financial expertBoard determined Mr. Titterton qualifies as an Audit Committee financial expert (SEC definition)
Meeting attendance (FY2024)Board: 7 meetings; all directors (incl. Titterton) attended all meetings eligible to attend
Committee attendance (FY2024)Audit: 6 meetings (≥75% attendance for each member); Compensation: 3 meetings (all attended); Nominating: 2 meetings (all attended)
Annual meeting attendanceAll then-serving directors/nominees attended 2024 annual meeting

Fixed Compensation (Director)

ComponentFY2024 Amount/Terms
Annual cash retainer$95,000, paid quarterly
Committee/Chair feesNot separately disclosed; retainer approved after review of comparable companies

Performance Compensation (Director)

InstrumentGrant dateSharesExercise priceTermVestingGrant-date fair value (FY2024)
Stock options (non-employee director annual grant)Jan 12, 202425,000$2.3710 yearsMonthly over one year$72,675

Additional option holdings: At October 31, 2024, Titterton held unexercised options to purchase 827,000 ANIX shares .

Other Directorships & Interlocks

CompanySectorRoleOverlap/Interlock Risk
ParkerVision, Inc.Wireless technologyDirectorNo ANIX-related related-party transactions disclosed

Expertise & Qualifications

  • Audit/finance expertise; designated Audit Committee financial expert
  • Extensive technology and healthcare operating/board experience; strategic development of technology companies
  • Board leadership experience (former ANIX Chairman; current Lead Independent Director)
  • Education: MBA (SUNY Albany), BA (Cornell)

Equity Ownership

MetricAmount/Detail
Total beneficial ownership1,763,501 ANIX shares; 5.3% of outstanding
Options exercisable within 60 days (2010 Plan)372,000 shares
Options exercisable within 60 days (2018 Plan)459,167 shares
Unexercised options held (all)827,000 options as of 10/31/2024
Section 16 complianceAll required filings made timely in FY2024 (company belief)

Governance Assessment

  • Strengths

    • Deep governance involvement: Lead Independent Director; chairs both Audit and Compensation; member of Nominating. Brings financial expertise (audit committee financial expert) and long institutional knowledge of ANIX .
    • Strong alignment via ownership: 5.3% beneficial ownership is material for a micro/small-cap, potentially aligning incentives with shareholders .
    • Engagement: Perfect board attendance; full committee attendance; attendance at annual meeting .
    • No related-party transactions disclosed; formal board review policy for any such transactions .
  • Watch items / potential red flags

    • Concentration of roles: Simultaneously serving as Lead Independent Director and chairing both Audit and Compensation centralizes oversight influence in one director; monitor for robust independent challenge and periodic committee rotation best practices .
    • Hedging policy gap: Company states it has no practices/policies restricting director/employee hedging; many investors prefer explicit prohibitions on hedging and pledging to ensure alignment .
    • Director fee structure: Proxy does not disclose incremental chair retainers (appears flat retainer plus options), which may underweight compensation for heightened chair workloads .
  • Compensation structure signals

    • Director pay mix includes equity via time-vested options (monthly vest over one year), providing at-risk exposure to share price; no performance-condition metrics disclosed for director awards .
    • Director compensation levels were set after reviewing comparable companies, but peer group composition not disclosed; continue to monitor for pay inflation absent disclosed benchmarks .
  • Independence and interlocks

    • Independent under Nasdaq/SEC rules; other public directorship at ParkerVision appears unrelated to ANIX’s business; no interlock conflicts or related-party exposure disclosed .
  • Succession and refreshment

    • Board size is four, with majority independent and a lead independent structure; continued monitoring of committee rotation and board refreshment is advisable given long-tenured service and concentrated responsibilities .